Clicky

Idorsia Ltd(IDIA) News

Date Title
Jun 30 A factory in a lab: Idorsia's breakthrough synthetic glycan vaccine platform validated for the first time in humans
Jun 25 Bondholders approve amended terms of the 2025 and 2028 convertible bonds
Jun 25 Idorsia launches repurchase offer for its 2025 and 2028 convertible bonds
Jun 23 Idorsia’s QUVIVIQ expands into China as Simcere receives NDA approval – Idorsia and Simcere update their licensing agreement
Jul 25 Idorsia announces financial results for the first half 2024
Jun 21 Idorsia’s novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality’ category
Jun 3 New data with daridorexant to be presented at SLEEP 2024
May 31 Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024
May 10 Q1 2024 Viatris Inc Earnings Call
May 6 Bondholders approve amended terms of the 2024 convertible bonds
Jan 10 Idorsia presents at the J.P. Morgan Healthcare Conference – Adapting Idorsia for sustainable value creation
Dec 6 Idorsia Ltd (VTX:IDIA) surges 19%; individual investors who own 41% shares profited along with insiders
Jul 10 Idorsia announces its insomnia medication, QUVIVIQ (daridorexant), is now covered by CVS